Abstracts tagged "Cohort Study"

Abstract Number: 0258 • ACR Convergence 2021
Developing Electronic Health Record Algorithms That Accurately Identify Patients with Juvenile Idiopathic Arthritis
Hannah Peterson¹, April Barnado² and Anna Patrick², ¹Lipscomb University College of Pharmacy, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Electronic Health Records (EHRs) store nearly all clinical data in one central location providing increased accessibility, accuracy, and security. At our institution, the Synthetic…
Abstract Number: 0816 • ACR Convergence 2021
Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting
Rieke Alten¹, Xavier Mariette², Rene-Marc Flipo³, Roberto Caporali⁴, Maya Buch⁵, Yusuf Patel⁶, Raimon Sanmarti⁷, Sara Marsal⁸, Michael Nurmohamed⁹, Hedley Griffiths¹⁰, Peter Peichl¹¹, Bettina Bannert¹², Adrian Forster¹³, Melanie Chartier¹⁴, Yedid Elbez¹⁵, Christiane Rauch¹⁶, Vadim Khaychuk¹⁷ and Karissa Lozenski¹⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Centre Hospitalier Universitaire de France, Lille, France, ⁴Policlinico S. Matteo University, Pavia, Italy, ⁵University of Leeds, Leeds, United Kingdom, ⁶Hull Royal Infirmary, Hull, United Kingdom, ⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, ¹⁰Barwon Rheumatology Service, Geelong, Australia, ¹¹Evangelical Hospital, Vienna, Austria, ¹²Universitätsspital Basel, Basel, Switzerland, ¹³Schulthess Klinik, Zürich, Switzerland, ¹⁴Bristol Myers Squibb, Rueil-Malmaison, France, ¹⁵Deepscover, Puteaux, France, ¹⁶Bristol Myers Squibb, Munich, Germany, ¹⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Longer disease duration and greater number of prior DMARDs have been associated with lower treatment efficacy in patients with RA.1 Abatacept is a biologic…
Abstract Number: 1427 • ACR Convergence 2021
Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sophie Dell’Aniello², Sofia Pedro³, Kaleb Michaud⁴ and Samy Suissa⁵, ¹University of Nebraska Medical Center, Bellevue, NE, ²Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montréal, QC, Canada, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital;Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montréal, QC, Canada
Background/Purpose: The risks of death and of type 2 diabetes mellitus (T2DM) are increased in RA mainly due to inflammation mediated accelerated cardiovascular disease (CVD)…
Abstract Number: 1879 • ACR Convergence 2021
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Elisheva Pokroy-Shapira¹, Iftach Sagy², Katya Meridor³ and Yair Molad⁴, ¹Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, Israel, ²Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ³Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ⁴Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel
Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
Abstract Number: 0368 • ACR Convergence 2021
Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Miranda van Lunteren¹, Anne Boel¹, Clementina López Medina², Joachim Sieper³, Désirée van der Heijde⁴ and Floris van Gaalen¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…
Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Nancy Guo¹, Xiuying Li², Mohammad Movahedi³, Angela Cesta⁴ and Claire Bombardier⁵, ¹Kingston General Hospital, Kingston, ON, Canada, ²OBRI at University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…
Abstract Number: 1493 • ACR Convergence 2021
Association of the Soluble Terminal Complement Complex C5b-9 (sC5b-9) with Urinary Signs of Kidney Disease in a Swiss SLE Cohort
Kristin Schmiedeberg¹, Ruediger B. Mueller², Thomas Neumann³, Ian Pirker¹, Philipp Rein⁴, Camillo Ribi⁵, Andrea Rubbert-Roth⁶, Michael Kirschfink⁷, Jutta Schroeder-Braunstein⁷, Reinhard Voll⁸ and Johannes von Kempis¹, ¹Kantonsspital St. Gallen, St.Gallen, Switzerland, ²Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ³Kantonsspital St.Gallen, St.Gallen, Switzerland, ⁴Landeskrankenhaus Hohenems, Wolfurt, Austria, ⁵CHUV, Lausanne, Switzerland, ⁶Kantonspital St Gallen, St.Gallen, Switzerland, ⁷Universitätsklinikum Heidelberg, Heidelberg, Germany, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
Background/Purpose: Few reliable laboratory biomarkers exist to determine disease activity in SLE. The role of the soluble terminal complement complex, sC5b-9, in active SLE has…
Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Ariane Barbacki¹, Ada Man², Mianbo Wang³, Dylan Johnson⁴, Yuqing Zhang⁵, Mandana Nikpour⁶ and Murray Baron⁷, ¹McGill University, Montral, Montréal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Lady Davis institute for Medical Research, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Massachusetts General Hospital, Quincy, MA, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
Abstract Number: 0826 • ACR Convergence 2021
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Miao Wang¹, Sylvie Lardeux², Elisea Avalos-Reyes³, Michele Hamburger⁴ and Kjel Johnson⁵, ¹CVS Health, New York, NY, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Lincoln, RI
Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…
Abstract Number: 1522 • ACR Convergence 2021
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
Anu Desai¹, Lakshmi Priya Shadananan¹, Adam Croft², Lalit Pallan¹, Neil Steven³ and Benjamin Fisher⁴, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Halesowen, United Kingdom, ³Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, ⁴Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
Abstract Number: 0417 • ACR Convergence 2021
Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Rula Hajj-Ali¹, Robert Butler², Carol Langford³, Leonard Calabrese², David Cuthbertson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih⁷, Kenneth Warrington¹³ and Peter Merkel⁷, ¹Cleveland Clinic, Hunting Valley, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, Minnesota
Background/Purpose: The prevalence of neurologic involvement (NI) in ANCA-associated vasculitis (AAV), especially central nervous system (CNS) involvement, is not well characterized. This project aimed to…
Abstract Number: 0827 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). We previously…
Abstract Number: 1539 • ACR Convergence 2021
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
Matas Orentas¹, Sonali Khandelwal², Michael Grant², Yanyu Zhang¹, Najia Shakoor² and Sobia Hassan¹, ¹RUMC, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
Abstract Number: 0450 • ACR Convergence 2021
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
Mark Hwang¹, Minjae Lee², Lianne Gensler³, Matthew Brown⁴, Amirali Tahanan⁵, Mohammad Rahbar⁶, Theresa Hunter⁷, Mingyan Shan⁸, Mariko Ishimori⁹, John Reveille¹⁰, Michael Weisman¹¹ and Thomas Learch¹², ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²UT Southwestern, Dallas, TX, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴King's College London, London, United Kingdom, ⁵McGovern Medical School, Houston, TX, ⁶Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁷Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Cedars-Sinai Health System, Los Angeles, CA, ¹⁰Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ¹¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹²Cedars-Sinai, Los Angeles, CA
Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…

1
2
3
…
9
Next Page »